Diethylcarbamazine disposition in patients with onchocerciasis

Geoffrey Edwards; Kwabla Awadzi; Alasdair M. Breckenridge; Herbert M. Gilles; Michael L.E. Orme; Steve Ward

doi:10.1038/clpt.1981.202

Diethylcarbamazine disposition in patients with onchocerciasis

Geoffrey Edwards, Kwabla Awadzi, Alasdair M. Breckenridge, Herbert M. Gilles, Michael L.E. Orme, Steve Ward

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

Diethylcarbamazine (DEC), 0.5 mg/kg, was taken orally by six patients being treated for onchocerciasis. Blood samples were taken at timed intervals for 48 hr and urine and feces collected for 4 days. Plasma and urinary concentrations of DEC and DEC N-oxide were measured by gas-liquid chromatography. DEC appeared to be rapidly, absorbed, with a peak plasma concentration of 150 to 250 ng/ml reached in 2 to 3 hr. There was a secondary rise in plasma DEC concentration at 5 to 6 hr in all patients. In contrast to the way the drug is eliminated in rats, in man it was by both renal and extrarenal routes, with small amounts (±10%) being excreted as an N-oxide metabolite. DEC kinetics were also investigated in five normal subjects and the results were much the same. Clinical implications are discussed.

Original language	English
Pages (from-to)	551-557
Number of pages	7
Journal	Clinical Pharmacology & Therapeutics
Volume	30
Issue number	4
DOIs	https://doi.org/10.1038/clpt.1981.202
Publication status	Published - 1 Oct 1981
Externally published	Yes

Access to Document

10.1038/clpt.1981.202

Cite this

@article{4bad3a025e6d4510bc6e55f6ea5e4328,

title = "Diethylcarbamazine disposition in patients with onchocerciasis",

abstract = "Diethylcarbamazine (DEC), 0.5 mg/kg, was taken orally by six patients being treated for onchocerciasis. Blood samples were taken at timed intervals for 48 hr and urine and feces collected for 4 days. Plasma and urinary concentrations of DEC and DEC N-oxide were measured by gas-liquid chromatography. DEC appeared to be rapidly, absorbed, with a peak plasma concentration of 150 to 250 ng/ml reached in 2 to 3 hr. There was a secondary rise in plasma DEC concentration at 5 to 6 hr in all patients. In contrast to the way the drug is eliminated in rats, in man it was by both renal and extrarenal routes, with small amounts (±10\%) being excreted as an N-oxide metabolite. DEC kinetics were also investigated in five normal subjects and the results were much the same. Clinical implications are discussed.",

author = "Geoffrey Edwards and Kwabla Awadzi and Breckenridge, \{Alasdair M.\} and Gilles, \{Herbert M.\} and Orme, \{Michael L.E.\} and Steve Ward",

year = "1981",

month = oct,

day = "1",

doi = "10.1038/clpt.1981.202",

language = "English",

volume = "30",

pages = "551--557",

journal = "Clinical Pharmacology \& Therapeutics",

number = "4",

}

TY - JOUR

T1 - Diethylcarbamazine disposition in patients with onchocerciasis

AU - Edwards, Geoffrey

AU - Awadzi, Kwabla

AU - Breckenridge, Alasdair M.

AU - Gilles, Herbert M.

AU - Orme, Michael L.E.

AU - Ward, Steve

PY - 1981/10/1

Y1 - 1981/10/1

N2 - Diethylcarbamazine (DEC), 0.5 mg/kg, was taken orally by six patients being treated for onchocerciasis. Blood samples were taken at timed intervals for 48 hr and urine and feces collected for 4 days. Plasma and urinary concentrations of DEC and DEC N-oxide were measured by gas-liquid chromatography. DEC appeared to be rapidly, absorbed, with a peak plasma concentration of 150 to 250 ng/ml reached in 2 to 3 hr. There was a secondary rise in plasma DEC concentration at 5 to 6 hr in all patients. In contrast to the way the drug is eliminated in rats, in man it was by both renal and extrarenal routes, with small amounts (±10%) being excreted as an N-oxide metabolite. DEC kinetics were also investigated in five normal subjects and the results were much the same. Clinical implications are discussed.

AB - Diethylcarbamazine (DEC), 0.5 mg/kg, was taken orally by six patients being treated for onchocerciasis. Blood samples were taken at timed intervals for 48 hr and urine and feces collected for 4 days. Plasma and urinary concentrations of DEC and DEC N-oxide were measured by gas-liquid chromatography. DEC appeared to be rapidly, absorbed, with a peak plasma concentration of 150 to 250 ng/ml reached in 2 to 3 hr. There was a secondary rise in plasma DEC concentration at 5 to 6 hr in all patients. In contrast to the way the drug is eliminated in rats, in man it was by both renal and extrarenal routes, with small amounts (±10%) being excreted as an N-oxide metabolite. DEC kinetics were also investigated in five normal subjects and the results were much the same. Clinical implications are discussed.

U2 - 10.1038/clpt.1981.202

DO - 10.1038/clpt.1981.202

M3 - Article

VL - 30

SP - 551

EP - 557

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 4

ER -

Diethylcarbamazine disposition in patients with onchocerciasis

Abstract

Access to Document

Fingerprint

Cite this